Next 10 |
2024-07-02 12:15:04 ET Canaccord Genuity analyst issues BUY recommendation for KRMD on July 2, 2024 10:05AM ET. The previous analyst recommendation was Buy. KRMD was trading at $2.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-07-02 12:00:07 ET Kyle Rose from Canaccord Genuity issued a price target of $3.00 for KRMD on 2024-07-02 10:05:00. The adjusted price target was set to $3.00. At the time of the announcement, KRMD was trading at $2.25. The overall price target consensus is at $4.50 ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announ...
The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”) and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC ® prefillable polymer syringes (PFS), intend to collaborate on optimization of drug delivery in the la...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) , a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today annou...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) , a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased ...
2024-05-01 22:11:08 ET KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Conference Call May 01, 2024 04:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer ...
2024-05-01 17:19:20 ET More on KORU Medical Systems KORU Medical Systems, Inc. 2024 Q1 - Results - Earnings Call Presentation KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript KORU Medical Systems announces successful appeal in EU notified body revie...
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
News, Short Squeeze, Breakout and More Instantly...
KORU Medical Systems Inc. Company Name:
KRMD Stock Symbol:
NYSE Market:
KORU Medical Systems Inc. Website:
2024-07-02 12:15:04 ET Canaccord Genuity analyst issues BUY recommendation for KRMD on July 2, 2024 10:05AM ET. The previous analyst recommendation was Buy. KRMD was trading at $2.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-07-02 12:00:07 ET Kyle Rose from Canaccord Genuity issued a price target of $3.00 for KRMD on 2024-07-02 10:05:00. The adjusted price target was set to $3.00. At the time of the announcement, KRMD was trading at $2.25. The overall price target consensus is at $4.50 ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announ...